Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.
Research published today identifies potential new ways to treat the most common type of colorectal cancer in Ireland. The study, conducted by an international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, provides a roadmap for repurposing existing drugs and developing new ones to create more effective, personalized treatments for thousands of patients who currently have limited options.
About 10% of cancers are linked to an inherited genetic variant, but as few as one in 15 cancer patients eligible for genetic testing complete it.
You might have heard that cardio, or aerobic, exercise is one of the best ways to keep your heart, lungs and cardiovascular system healthy and strong.
In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.
New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
New research indicates that U.S.–Mexico border counties experience disproportionately elevated rates of death from chronic kidney disease (CKD), alongside reduced availability of nephrologists. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in tacrolimus-treated patients at each reported time point, with a statistically significant kidney function benefit at 18 months. A recent analysis of BESTOW data found that tegoprubart also caused greater improvements in patient-reported health-related quality of life compared with tacrolimus in study participants. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is the dense tissue surrounding the tumor that acts as a protective barrier and suppresses the immune response. It is a complex tissue made of supporting cells, blood vessels and immune cells—the tumor microenvironment. In pancreatic cancer, this surrounding tissue accounts for up to 90% of the tumor mass.
Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life.
For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according to a study published in the Oct. 15 issue of the New England Journal of Medicine.
An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. The findings, published in Nature Medicine, will help researchers design a larger phase 3 clinical trial.
Kenya's Health Ministry announced the country's second Ebola death Friday, saying a 65-year-old woman who was a close relative of the first patient died after developing symptoms while in quarantine.
The first clinical trial of an Ebola vaccine in the outbreak gripping the Democratic Republic of Congo began Friday, the head of the World Health Organization said.
Much like a satellite provides a full picture of Earth, a new technology can generate thousands of detailed "satellite maps" showing where individual proteins are located and distributed across an entire tissue in the body or brain.
---- End of list Med Xpress News Articles on this page 2 of 2 total pages ----